Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Leflunomide for active rheumatoid arthritis].

P N Andresen1, G Hansen, K Hørslev-Petersen

  • 1Kong Christian X's Gigthospital, Gråsten.

Ugeskrift for Laeger
|October 24, 2000
PubMed
Summary

Leflunomide, a pyrimidine synthesis inhibitor, effectively treats rheumatoid arthritis with a dosing regimen and monitoring schedule. It offers an alternative when other treatments like methotrexate fail.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

scRNA-seq reveals persistent aberrant differentiation of nasal epithelium driven by TNFα and TGFβ in post-COVID syndrome.

Nature communications·2025
Same author

Plasma haem oxygenase-1 may represent a first-in-class biomarker of oxidative stress in rheumatoid arthritis.

Scandinavian journal of rheumatology·2024
Same author

Increased breath naphthalene in children with asthma and wheeze of the All Age Asthma Cohort (ALLIANCE).

Journal of breath research·2023
Same author

Baseline serum levels of IgA anti-cyclic citrullinated protein antibodies in early rheumatoid arthritis predict radiographic progression after 11 years of treatment: a secondary analysis of the CIMESTRA study.

Scandinavian journal of rheumatology·2022
Same author

Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial.

Scandinavian journal of rheumatology·2022
Same author

An examination of mercury levels in the coastal environment and fish of Cote d'Ivoire.

Chemosphere·2022

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Leflunomide, introduced in 1999, targets active rheumatoid arthritis.
  • It functions as a reversible inhibitor of pyrimidine synthesis, restricting lymphocyte proliferation.
  • Its slow elimination pharmacodynamics are notable.

Purpose of the Study:

  • To review the efficacy and safety of leflunomide in rheumatoid arthritis treatment.
  • To outline the recommended dosing, monitoring, and discontinuation procedures for leflunomide.
  • To position leflunomide within the existing treatment landscape for rheumatoid arthritis.

Main Methods:

  • Review of leflunomide's mechanism of action and pharmacokinetic profile.
  • Analysis of clinical efficacy and side effect patterns compared to methotrexate and sulphasalazine.
  • Description of standard treatment initiation, maintenance, and termination protocols.

Main Results:

  • Leflunomide demonstrates efficacy comparable to methotrexate and sulphasalazine.
  • Common side effects are mild, but serious adverse events can occur.
  • A specific loading dose followed by a daily maintenance dose is recommended.

Conclusions:

  • Leflunomide is a viable treatment option for active rheumatoid arthritis.
  • It is particularly indicated after treatment failure with methotrexate or sulphasalazine.
  • Careful monitoring and adherence to drug elimination procedures are essential.

Related Experiment Videos